Literature DB >> 10206490

Immunohistochemical and molecular analysis of giant cell carcinoma of the pancreas: a report of three cases.

Y Imai1, S Morishita, Y Ikeda, M Toyoda, T Ashizawa, K Yamamoto, T Inoue, T Ishikawa.   

Abstract

We performed molecular biological studies as well as immunohistochemical analysis of three cases of giant cell carcinoma of the pancreas. Histologically, one case was a pleomorphic giant cell carcinoma consisting of pleomorphic giant/ small cells and spindle cells, one an osteoclast-like giant cell tumor composed of osteoclastoid giant cells and pleomorphic small cells, and one a pleomorphic giant cell carcinoma with osteoclastoid giant cells. Immunohistochemically, pleomorphic giant cells and small pleomorphic cells were positive for epithelial and mesenchymal markers throughout the cases. Osteoclastoid cells were strongly positive for PG-M1 (CD68), but negative for lysozyme and epithelial markers. Pleomorphic spindle cells showed the same immunoreactivity as pleomorphic giant/small cells. Genetically, all cases contained a mutation in the K-ras (codons 12, 13) oncogene, but neither p53 (exons 5-8) nor p16INK4 (exons 1, 2) gene mutations were found in any case. Furthermore, Loss of heterozygosity (LOH) of the p53, p161NK4. APC, and DPC4 gene loci was not found in any of the cases. Immunohistochemical study demonstrated this tumor to be of epithelial origin with mesenchymal differentiation. Genetically, initiation of the tumor is similar to that of usual ductal adenocarcinoma, but progression might be rather different. The peculiar histologic and biologic features of this tumor would be the result of changes in other functional genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206490     DOI: 10.1097/00006676-199904000-00013

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Osteoclast-like giant cell tumors of the pancreas and liver.

Authors:  Juergen Bauditz; Birgit Rudolph; Wolfram Wermke
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  In vitro induction of giant cell tumors from cultured hamster islets treated with N-Nitrosobis(2-Oxopropyl)amine.

Authors:  H Matsuzaki; B M Schmied; A Ulrich; S K Batra; P M Pour
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

Review 3.  Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance.

Authors:  Sarah R Amend; Gonzalo Torga; Ke-Chih Lin; Laurie G Kostecka; Angelo de Marzo; Robert H Austin; Kenneth J Pienta
Journal:  Prostate       Date:  2019-08-02       Impact factor: 4.104

4.  A case of osteoclast-like giant cell tumor of the pancreas with ductal adenocarcinoma: histopathological, immunohistochemical, ultrastructural and molecular biological studies.

Authors:  Young-Eun Joo; Tag Heo; Chang-Hwan Park; Wan-Sik Lee; Hyun-Soo Kim; Jung-Chul Kim; Yang-Seok Koh; Sung-Kyu Choi; Chol-Kyoon Cho; Jong-Sun Rew; Sei-Jong Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

Review 5.  The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians.

Authors:  Günter Klöppel; Jutta Lüttges
Journal:  Curr Gastroenterol Rep       Date:  2004-04

6.  Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis.

Authors:  Guangjian Yang; Jiangxia Yin; Kai Ou; Qiang Du; Wenhao Ren; Yujing Jin; Liming Peng; Lin Yang
Journal:  BMC Gastroenterol       Date:  2020-06-26       Impact factor: 3.067

Review 7.  Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.

Authors:  Chiara Bazzichetto; Claudio Luchini; Fabiana Conciatori; Vanja Vaccaro; Ilaria Di Cello; Paola Mattiolo; Italia Falcone; Gianluigi Ferretti; Aldo Scarpa; Francesco Cognetti; Michele Milella
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.